Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | Director | May 19, 2025 | May 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date May 19, 2025 · Filed May 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 32,954 |
Reported balance
After 2025-05-19 transaction · row 1
1 source rowRow 1 · 2025-05-19 · Grant · Acquired 10,649 · Balance 32,954 |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2035-05-18 | Direct | 24,258 |
Reported balance
After 2025-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-19 · Grant · Acquired 24,258 · Balance 24,258 F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2025 Filed May 21, 2025 19:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 24,258 | $0.00 Strike: $9.39 | $0.00 |
DisclosureSEC source: 0001415889-25-014005 · form4-05212025_110527.xml · derivative · entry 2 Grant Jeremy T · CIK 0002004368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,258 Underlying: Ordinary Shares · 24,258 shares Expires 2035-05-18 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 19, 2025 Filed May 21, 2025 19:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 10,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014005 · form4-05212025_110527.xml · nonDerivative · entry 1 Grant Jeremy T · CIK 0002004368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,954 Read SEC document |
| May 08, 2024 Filed May 10, 2024 18:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 23,576 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001415889-24-012911 · form4-05102024_100529.xml · derivative · entry 2 Grant Jeremy T · CIK 0002004368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,576 Underlying: Ordinary Shares · 23,576 shares Expires 2034-05-07 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 08, 2024 Filed May 10, 2024 18:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 10,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012911 · form4-05102024_100529.xml · nonDerivative · entry 1 Grant Jeremy T · CIK 0002004368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,305 Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 18:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,578 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001415889-23-016943 · form4-12262023_111258.xml · derivative · entry 4 Grant Jeremy T · CIK 0002004368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,578 Underlying: Ordinary Shares · 6,578 shares Expires 2033-12-21 F2 · derivative.exercise_date: This option shall vest monthly over four months of service from the date of grant and will vest in full upon earlier of the four-month anniversary of Jeremy Grant's appointment to the Board or the date of Company's 2024 annual meeting of Shareholders. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 18:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 19,734 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001415889-23-016943 · form4-12262023_111258.xml · derivative · entry 3 Grant Jeremy T · CIK 0002004368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,734 Underlying: Ordinary Shares · 19,734 shares Expires 2033-12-21 F1 · derivative.exercise_date: The option vests monthly over 24 months of service from the date of grant. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 18:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 2,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-016943 · form4-12262023_111258.xml · nonDerivative · entry 2 Grant Jeremy T · CIK 0002004368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,768 Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 18:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-016943 · form4-12262023_111258.xml · nonDerivative · entry 1 Grant Jeremy T · CIK 0002004368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,826 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.